|
|
| Line 3: |
Line 3: |
| | <StructureSection load='6ani' size='340' side='right'caption='[[6ani]], [[Resolution|resolution]] 2.40Å' scene=''> | | <StructureSection load='6ani' size='340' side='right'caption='[[6ani]], [[Resolution|resolution]] 2.40Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6ani]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Camelus_glama Camelus glama] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ANI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ANI FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6ani]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ANI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ANI FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.4Å</td></tr> |
| - | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=UNK:UNKNOWN'>UNK</scene></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ani FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ani OCA], [http://pdbe.org/6ani PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ani RCSB], [http://www.ebi.ac.uk/pdbsum/6ani PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ani ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ani FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ani OCA], [https://pdbe.org/6ani PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ani RCSB], [https://www.ebi.ac.uk/pdbsum/6ani PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ani ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 20: |
Line 20: |
| | ==See Also== | | ==See Also== |
| | *[[Antibody 3D structures|Antibody 3D structures]] | | *[[Antibody 3D structures|Antibody 3D structures]] |
| | + | *[[3D structures of non-human antibody|3D structures of non-human antibody]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Camelus glama]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Human]] | + | [[Category: Lama glama]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Julien, J P]] | + | [[Category: Ereno Orbea J]] |
| - | [[Category: Orbea, J Ereno]] | + | [[Category: Julien J-P]] |
| - | [[Category: Sicard, T]] | + | [[Category: Sicard T]] |
| - | [[Category: Antibody]]
| + | |
| - | [[Category: Cd19]]
| + | |
| - | [[Category: Fab]]
| + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Vhh domain]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Monoclonal antibodies constitute one of the largest groups of drugs to treat cancers and immune disorders, and are guiding the design of vaccines against infectious diseases. Fragments antigen-binding (Fabs) have been preferred over monoclonal antibodies for the structural characterization of antibody-antigen complexes due to their relatively low flexibility. Nonetheless, Fabs often remain challenging to crystallize because of the surface characteristics of complementary determining regions and the residual flexibility in the hinge region between the variable and constant domains. Here, we used a variable heavy-chain (VHH) domain specific for the human kappa light chain to assist in the structure determination of three therapeutic Fabs that were recalcitrant to crystallization on their own. We show that this ligand alters the surface properties of the antibody-ligand complex and lowers its aggregation temperature to favor crystallization. The VHH crystallization chaperone also restricts the flexible hinge of Fabs to a narrow range of angles, and so independently of the variable region. Our findings contribute a valuable approach to antibody structure determination and provide biophysical insight into the principles that govern the crystallization of macromolecules.
Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments.,Ereno-Orbea J, Sicard T, Cui H, Carson J, Hermans P, Julien JP J Mol Biol. 2017 Dec 22. pii: S0022-2836(17)30591-0. doi:, 10.1016/j.jmb.2017.12.010. PMID:29277294[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Ereno-Orbea J, Sicard T, Cui H, Carson J, Hermans P, Julien JP. Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments. J Mol Biol. 2017 Dec 22. pii: S0022-2836(17)30591-0. doi:, 10.1016/j.jmb.2017.12.010. PMID:29277294 doi:http://dx.doi.org/10.1016/j.jmb.2017.12.010
|
